
RealRate

PHARMACEUTICAL 2020

MANNKIND CORP Rank 320 of 358

mannkind





PHARMACEUTICAL 2020

MANNKIND CORP Rank 320 of 358



The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -201%, being 237% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	60,757
Cost of Goods Sold	20,078
Intangible Assets	0
Liabilities, Current	65,618
Liabilities, Non-Current	10,858
Other Assets	6,190
Other Compr. Net Income	0
Other Expenses	5,988
Other Liabilities	207,775
Other Net Income	-7,306
Other Revenues	63,038
Property and Equipment	26,778
Research and Development	6,900
Selling, General and Administrative Expense	74,669

Output Variable	Value in 1000 USD
Assets	93,725
Liabilities	284,251
Expenses	107,635
Revenues	63,038
Stockholders Equity	-190,526
Net Income	-51,903
Comprehensive Net Income	-51,903
Economic Capital Ratio	-201%

